Literature DB >> 12869586

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.

Ken Inoki1, Yong Li, Tian Xu, Kun-Liang Guan.   

Abstract

Tuberous sclerosis complex (TSC) is a genetic disease caused by mutation in either TSC1 or TSC2. The TSC1 and TSC2 gene products form a functional complex and inhibit phosphorylation of S6K and 4EBP1. These functions of TSC1/TSC2 are likely mediated by mTOR. Here we report that TSC2 is a GTPase-activating protein (GAP) toward Rheb, a Ras family GTPase. Rheb stimulates phosphorylation of S6K and 4EBP1. This function of Rheb is blocked by rapamycin and dominant-negative mTOR. Rheb stimulates the phosphorylation of mTOR and plays an essential role in regulation of S6K and 4EBP1 in response to nutrients and cellular energy status. Our data demonstrate that Rheb acts downstream of TSC1/TSC2 and upstream of mTOR to regulate cell growth.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869586      PMCID: PMC196227          DOI: 10.1101/gad.1110003

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  34 in total

1.  Phenotypes of the tuberous sclerosis complex with a revision of diagnostic criteria.

Authors:  M R Gomez
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

2.  A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants.

Authors:  M Trahey; F McCormick
Journal:  Science       Date:  1987-10-23       Impact factor: 47.728

3.  Identification of the coding sequences responsible for Tsc2-mediated tumor suppression using a transgenic rat system.

Authors:  Shuji Momose; Toshiyuki Kobayashi; Hiroaki Mitani; Masumi Hirabayashi; Kazumi Ito; Masatsugu Ueda; Yo-ichi Nabeshima; Okio Hino
Journal:  Hum Mol Genet       Date:  2002-11-15       Impact factor: 6.150

Review 4.  Function and regulation of ras.

Authors:  D R Lowy; B M Willumsen
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

5.  Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.

Authors:  Heidi L Kenerson; Lauri D Aicher; Lawrence D True; Raymond S Yeung
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

Review 6.  Regulation of mammalian translation factors by nutrients.

Authors:  Christopher G Proud
Journal:  Eur J Biochem       Date:  2002-11

7.  Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Elena A Goncharova; Dmitry A Goncharov; Andrew Eszterhas; Deborah S Hunter; Marilyn K Glassberg; Raymond S Yeung; Cheryl L Walker; Daniel Noonan; David J Kwiatkowski; Margaret M Chou; Reynold A Panettieri; Vera P Krymskaya
Journal:  J Biol Chem       Date:  2002-06-03       Impact factor: 5.157

8.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.

Authors:  Ken Inoki; Yong Li; Tianquan Zhu; Jun Wu; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

Review 9.  Tuberous sclerosis: from tubers to mTOR.

Authors:  D J Kwiatkowski
Journal:  Ann Hum Genet       Date:  2003-01       Impact factor: 1.670

10.  Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.

Authors:  Andrew R Tee; Diane C Fingar; Brendan D Manning; David J Kwiatkowski; Lewis C Cantley; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

View more
  774 in total

1.  Regulation of mTORC1 by the Rab and Arf GTPases.

Authors:  Li Li; Eunjung Kim; Haixin Yuan; Ken Inoki; Pankuri Goraksha-Hicks; Rachel L Schiesher; Thomas P Neufeld; Kun-Liang Guan
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

Review 2.  Deconvoluting mTOR biology.

Authors:  Jason D Weber; David H Gutmann
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

3.  TGFβ acts through PDGFRβ to activate mTORC1 via the Akt/PRAS40 axis and causes glomerular mesangial cell hypertrophy and matrix protein expression.

Authors:  Soumya Maity; Falguni Das; Balakuntalam S Kasinath; Nandini Ghosh-Choudhury; Goutam Ghosh Choudhury
Journal:  J Biol Chem       Date:  2020-07-30       Impact factor: 5.157

Review 4.  MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells.

Authors:  Russell G Jones; Edward J Pearce
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

5.  Curcumin disrupts the Mammalian target of rapamycin-raptor complex.

Authors:  Christopher S Beevers; Long Chen; Lei Liu; Yan Luo; Nicholas J G Webster; Shile Huang
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 6.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

7.  The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.

Authors:  T R Hartman; E Nicolas; A Klein-Szanto; T Al-Saleem; T P Cash; M C Simon; E P Henske
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

8.  Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation.

Authors:  Andreas G Bader; Peter K Vogt
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 9.  Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer.

Authors:  Michelle J Lee; Nan Jin; Jennifer R Grandis; Daniel E Johnson
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-02-19       Impact factor: 4.739

Review 10.  Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.

Authors:  Scott T Eblen
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.